Apricot Therapeutics is the first company to coin the concept of spatial drug activity contexts or DACs. Mapping the spatial context of genome activity, known as genomics 3.0, will re-define drug development and medicine in the next decade. DACs capture how the various spatial organisations of the products of our genome cause drugs to have variable effects. Apricot's unique platform comprehensively maps DACs at all biological scales relevant for drug discovery. This reveals the predictive rules by which spatial context across scales determines cellular responses to drugs and treatment outcomes.